The Future of CRISPR-Engineered Stem Cell Therapies: Virtual Event Audience Q&A
The introduction of the CRISPR technology and the ability to grow stem cells in the lab have been among the most important breakthroughs in the scientific world. CRISPR-engineered stem cell therapies have made tremendous advancements in the past 5 years, but challenges still exist. From understanding that CRISPR is in fact safe if used in the appropriate context to learning how CRISPR affords potential for immediate patient impact, there is no need to question the permanency of gene editing.
To learn more about CRISPR gene editing, Cell and Gene Chief Editor, Erin Harris, sat down with Sadik Kassim, Chief Technical Officer at Vor Biopharma to discuss the benefits of CRISPR-engineered stem cell therapies, the challenges and feasible solutions, and what's next.
Sadik tackles the audience’s questions about total treatment cost; the use of gene insertion; lessons learned from CRISPR trials, and more.
Get unlimited access to:
Enter your credentials below to log in. Not yet a member of Cell & Gene? Subscribe today.